Dynamic serum tumor-marker and immune-inflammatory biomarker changes for risk stratification of immune checkpoint inhibitor-associated myasthenia gravis in non-small cell lung cancer
Pin Cui, Xiaohui Lin, Weimin Luo, Shaorong Zhang, Song Zhang, Shu Xu, Junming Lai, Yong Xiong, Dehong Chen, Binding Huang, Zhiming Xu · 2026
Read Dynamic serum tumor-marker and immune-inflammatory biomarker changes for risk stratification of immune checkpoint inhibitor-associated myasthenia gravis in non-small cell lung cancer by Pin Cui, Xiaohui Lin, Weimin Luo, Shaorong Zhang, Song Zhang, Shu Xu, Junming Lai, Yong Xiong, Dehong Chen, Binding Huang, Zhiming Xu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13600999.txt.
Description
Cui and a large team test in twenty twenty-six whether early blood changes can flag lung cancer patients at risk of a rare immune side effect. Some patients on immune-boosting cancer drugs develop a muscle-weakness disease within months, sometimes with heart or muscle inflammation too. The team tracked tumour markers and inflammation ratios in over eight hundred patients starting such therapy.
Patients who later developed the weakness showed bigger early rises in several markers and a steeper drop in a key blood protein by week three. A four-part score built from those shifts split patients into risk bands with clearly different event rates. The authors offer the score for watchful monitoring, while noting it needs outside checks.
Catalog record
| CREATOR | Pin Cui, Xiaohui Lin, Weimin Luo, Shaorong Zhang, Song Zhang, Shu Xu, Junming Lai, Yong Xiong, Dehong Chen, Binding Huang, Zhiming Xu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 69 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |